Patent EP0154142A1 successfully refreshed from Google Patents.
EP0154142A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Substituted hexahydro arylquinolizines
Assignee: Merck and Co Inc
•
Filing: 1985-01-25
•
Granted: —
•
Expires: 2005-01-25
Abstract
Abstract Substituted heitahydro arylquinolizines and pharmaceutically acceptable salts thereof are selective I X2-adrenergic receptor antagonists and thereby useful as antidepressants, antihypeftensives, antidiabetics, and platelet aggregation inhibitors.
Inventors
- 👤 Joel R. Huff
- 👤 Joseph P. Vacca
- 👤 John J. Baldwin
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 18:30
CPC Classifications
C; C07; C07D; C07D471/00; C07D471/02; C07D471/04; C07D307/00; C07D307/77; C07D307/78; C07D307/79; A; A61; A61P; A61P25/00; A61P25/02; A61P25/24; A61P25/26; A61P3/00; A61P3/08; A61P7/00; A61P7/02; A61P9/00; A61P9/12; C07D307/81; C07D471/12; C07D471/14; C07D491/00; C07D491/02; C07D491/04; C07D491/12; C07D491/14; C07D495/00; C07D495/12; C07D495/14; C07D513/00; C07D513/12; C07D513/14
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
419 words
A compound of structural formula: or a pharmaceutically acceptable salt thereof wherein Ar represents an aromatic heterocycle selected from R 1 ,R 2 -benzo[b]furo-, R 1 ,R 2 -benzo[b]thieno-, pyridino-, thiazolo-, imidazo-, pyrazolo-, thieno- and furo-; R l and R 2 are independently: 1) hydrogen, 2) halo, 3) hydroxy, 4 ) C 1-3 alkoxy, or 5) C 1-6 alkyl; R 3 is 1) hydrogen, 2) wherein R is hydrogen or C 1-3 alkyl, 3) C 1-6 a3kyl, either unsubstituted or substituted with one or more of; a) hydroxy, b) carboxy, c ) C 1-3 alkoxycarbonyl, d) halo, e ) C 1-3 alkoxy, f) -CONR 6 R 7 , wherein R 6 and R 7 are the same or different and are hydrogen or C 1-5 alkyl, or joined together directly to form a 5-7 membered ring or through a heteroatom selected from 0, N and S, to form a 6-membered heterocycle with the nitrogen to which they are attached, or g ) - NR 6 R 7 ; X is R 4 is 1) -OR 8 , wherein R 8 is hydrogen or C 1-6 alkyl, either unsubstituted or substituted with one or more of; a) OR, or b) -NRCOR; 2) -N(R 8 ) 2 , 3) -CO 2 R 8 , 4) -CONR 6 R 7 , 5) C 1-6 alkyl, either unsubstituted or substituted with a) OR 8 , b) halo, c) CO 2 R 8 , d) CONR 6 R 7 , 6) C 2-5 alkenyl, 7 ) C 2 _,alkynyl, 8 ) C 3-6 cycloalkyl, 9) 5 or 6-membered heterocycle with up to 2 heteroatoms selected from N, 0, and S, 10) carbocyclic aryl of 6-10 carbon atoms, either unsubstituted or substituted with one or more of; a) halo, or b) OR; or 5 R is 1) hydrogen, <) C 1-3 alkgl, 2) C 1-6 alkyl, either unsubstituted or substituted with one or more of a) -OR 8 , b) -NR 8 COR 8 , or c) -CO 2 R 8 , 3) -CO 2 R 8 , or 4) -CONR 6 R 7 ; R 3 and R 4 taken together directly or through a - heteroatom selected from O, N and S, form a 5- or 6-membered heterocycle with the nitrogen to which they are attached; or R 3 and R 5 or R 4 and R 5 , if R 5 is in the 1- or 3-position and both are alkyl, can be joined together to form a 5- or 6-membered ring.
Claim 2
Dependent Claim
419 words
A compound of structural formula: or a pharmaceutically acceptable salt thereof wherein Ar represents an aromatic heterocycle selected from R 1 ,R 2 -benzo[b]furo-, R 1 ,R 2 -benzo[b]thieno-, pyridino-, thiazolo-, imidazo-, pyrazolo-, thieno- and furo-; R l and R 2 are independently: 1) hydrogen, 2) halo, 3) hydroxy, 4 ) C 1-3 alkoxy, or 5) C 1-6 alkyl; R 3 is 1) hydrogen, 2) wherein R is hydrogen or C 1-3 alkyl, 3) C 1-6 a3kyl, either unsubstituted or substituted with one or more of; a) hydroxy, b) carboxy, c ) C 1-3 alkoxycarbonyl, d) halo, e ) C 1-3 alkoxy, f) -CONR 6 R 7 , wherein R 6 and R 7 are the same or different and are hydrogen or C 1-5 alkyl, or joined together directly to form a 5-7 membered ring or through a heteroatom selected from 0, N and S, to form a 6-membered heterocycle with the nitrogen to which they are attached, or g ) - NR 6 R 7 ; X is R 4 is 1) -OR 8 , wherein R 8 is hydrogen or C 1-6 alkyl, either unsubstituted or substituted with one or more of; a) OR, or b) -NRCOR; 2) -N(R 8 ) 2 , 3) -CO 2 R 8 , 4) -CONR 6 R 7 , 5) C 1-6 alkyl, either unsubstituted or substituted with a) OR 8 , b) halo, c) CO 2 R 8 , d) CONR 6 R 7 , 6) C 2-5 alkenyl, 7 ) C 2 _,alkynyl, 8 ) C 3-6 cycloalkyl, 9) 5 or 6-membered heterocycle with up to 2 heteroatoms selected from N, 0, and S, 10) carbocyclic aryl of 6-10 carbon atoms, either unsubstituted or substituted with one or more of; a) halo, or b) OR; or 5 R is 1) hydrogen, <) C 1-3 alkgl, 2) C 1-6 alkyl, either unsubstituted or substituted with one or more of a) -OR 8 , b) -NR 8 COR 8 , or c) -CO 2 R 8 , 3) -CO 2 R 8 , or 4) -CONR 6 R 7 ; R 3 and R 4 taken together directly or through a - heteroatom selected from O, N and S, form a 5- or 6-membered heterocycle with the nitrogen to which they are attached; or R 3 and R 5 or R 4 and R 5 , if R 5 is in the 1- or 3-position and both are alkyl, can be joined together to form a 5- or 6-membered ring.
Claim 3
Dependent Claim
102 words
The compound of Claim 1 or a pharmaceutically acceptable salt thereof wherein Ar is R 1 ,R 2 -benzo[b]furo- or R 1 ,R 2 -benzo[blthieno-; R 1 and R 2 are hydrogen or halo; R 3 is C 1-6 alkyl, X is -SO 2 - and R 4 is C 1-6 alkyl, di(C 1-3 alkyl)-amino, halo-C 1-6 alkyl, hydroxy-C 1-6 alkyl, C 2-5 alken y l, C 6-10 carbocyclic aryl, 5 or 6-membered heterocycle, -CO 2 R 8 , -C 1-6 alkyl-CO 1 R 8 or -C 1-6 alkyl-CONR 6 R 7 ; and R 5 is hydrogen or C 1-6 alkyl.
Claim 4
Dependent Claim
27 words
The compound of Claim 2 which is: a) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2ß-yl)-N-methyl-2-hydroxyethanesulfon- amide; b) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2H-yl)-N-methyl-3-hydroxypropanesulfon- amide; c) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2ß-yl)-N-methyl-3-methanesulfonamide; d) (+)-N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo-[2,3a]quinolizin-2ß-yl)-N,,N',,N'-trimethylsulfamide; or e) -N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]thieno-[2,3a]quinolizin-2ß-yl)-N-methyl-methanesulfon- amide; or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
54 words
A pharmaceutical composition having a 2 -adrenoceptor antagonist activity comprising a pharmaceutically acceptable carrier and an effective a 2 -adrenoceptor antagonist amount of a compound of structural formula: or a pharmaceutically acceptable salt thereof, wherein A r, R 3 , X , R 5 , and R 4 are as defined in Claim 1.
Claim 6
Dependent Claim
91 words
The composition of Claim 4 wherein Ar is R 1 ,R 2 benzo[b]furo- or R 1 ,R2-benzo[bl-thieno-; R 1 and R 2 are hydrogen or halo; R 3 is C 1-6 alkyl, X is -SO 2 - and R 4 is C 1-6 alkyl, di(C 1-3 alkyl)amino, halo-C 1-6 alkyl, hydroxy-C 1-6 alkyl, C2 -5a lkenyl , C 6-10 carbocyclic aryl, 5 or 6-membered heterocycle, -CO 2 R 8 , -C 1-5 alkyl-CO 2 or -C 1-6 -alkyl-CONR 6 R 7 , and R 5 is hydrogen or C 1-6 alkyl.
Claim 7
Dependent Claim
31 words
The pharmaceutical composition of Claim 5 wherei the compound is: a) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2B-yl)-N-methyl-2-hydroxyethanesulfon- amide; b) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2ß-yl)-N-methyl-3-hydroxypropanesulfon- amide; c) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2ß-yl)-N-methyl-3-methanesulfonamide; d) (+)-N-(1,3,4,6,7,12ba-hexahydro-2H-benzo[b]furo-[2,3a]quinolizin-2B-yl)-N,N',N'-trimethylsulf- amide; or e) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]thieno-[2,3a]quinolizin-2B-yl)-N-methyl-methanesulfon- amide; or a pharmaceutically acceptable salt thereof.
Claim 8
Independent Claim
57 words
A method of antagonizing a 2 -adrenoceptors which comprises administering to a patient in need of such treatment an effective α 2 - adrenoceptor antagonist amount of a compound of structural formula: or a pharmaceutically acceptable salt thereof wherein Ar, R 3 , X , R 4 , and R 5 are as defined in Claiml .
Claim 9
Independent Claim
93 words
The method of Claim wherein Ar is R 1 ,R 2 -benzo[b]furo or R 1 ,R 2 -benzo[b]thieno; R 1 and R 2 are hydrogen or halo; R 3 is C 1-6 alkyl; X is -S0 2 - and R 4 is C 1-6 alkyl, di(C 1-3 alkyl)amino, halo-C 1-6 alkyl, hydroxy-C 1-6 alkyl, C 2-5 alkenyl, C 6-10 -carbocyclic aryl, 5 or 6-membered heterocycle, -CO 2 R 8 , -C 1-6 alkyl-CO 2 R 8 or C 1-6 alkyl-CONR 6 R 7 ; and R 5 is hydrogen or C 1-6 alkyl.
Claim 10
Dependent Claim
30 words
The method of Claim 8 wherein the compound is: a) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2B-yl)-N-methyl-2-hydroxyethanesulfon- amide; b) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2ß-yl)-N-methyl-3-hydroxypropanesulfon- amide; c) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]furo[2,3a]-quinolizin-2ß-yl)-N-methyl-methanesulfonamide; d) (+)-N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]faro-[2,3a]quinolizin-2ß-yl)-N,N',N'-trimethylsulf- amide; or e) N-(1,3,4,6,7,12bα-hexahydro-2H-benzo[b]thieno-[2,3a]quinolizin-2H-yl)-N-methyl-methanesulfon- amide; or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
18 words
The compound of Claim 2 or a pharmaceutically acceptable salt thereof with a 12ba,2B configuration and its enantiomers.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.